Für Ärzte/Ärztinnen

Ich lege großen Wert auf eine vertrauensvolle Zusammenarbeit mit dem zuweisenden Arzt. Bitte kontaktieren Sie mich hierfür per

E-Mail: info@reizdarm-sibo.de

oder per Klick auf diesen Link:

Nachricht senden

Hier gibt es Unterstützung für die Betreuung Ihrer Reizdarm-Patienten:

Infos zu geeigneten Atemtests bei SIBO

Ein SIBO-Atemtest sollte Ihnen und Ihren Patienten individuelle und differenzierte Testergebnisse liefern, gemäß aktuellster wissenschaftlicher Erkenntnisse und unter Einbeziehung der Expertise international führender SIBO-Ärzte!

Hier geht es direkt zu einem beispielhaften SIBO-Atemtest

Ergänzende Links zu Studien und anderen Dokumenten:

REIZDARM

Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome (IBS).

https://www.ncbi.nlm.nih.gov/pubmed/30611316

A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.

https://www.ncbi.nlm.nih.gov/pubmed/30406392

Launch of ibs-smart™, an advancement in blood testing for Irritable Bowel Syndrome (IBS)

https://www.prnewswire.com/news-releases/launch-of-ibs-smart-an-advancement-in-blood-testing-for-irritable-bowel-syndrome-ibs-announced-by-gemelli-biotech-in-partnership-with-the-medically-associated-science-and-technology-program-mast-at-cedars-sinai-300728775.html

Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.

https://www.ncbi.nlm.nih.gov/pubmed/28451914

Cedars-Sinai Research Identifies Gut Gas Linked to Diarrhea (Hydrogen Sulfide)

https://www.cedars-sinai.org/newsroom/cedars-sinai-research-identifies-gut-gas-linked-to-diarrhea/

Review of rifaximin as treatment for SIBO and IBS

https://www.ncbi.nlm.nih.gov/pubmed/19243285

Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.

https://www.ncbi.nlm.nih.gov/pubmed/29508268

Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/

Update on Irritable Bowel Syndrome Diagnostics and Therapeutics

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/

IBSchek - The First Clinically Validated Blood Test for IBS with Predominant Diarrhea (IBS-D) and Mixed Symptoms (IBS-M)

http://www.commdx.com/irritable-bowel-syndrome.html

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/11151884/

25 % aller Nicht-Antibiotika schädigen Darmbakterien

https://www.ernaehrungsmedizin.blog/2018/03/20/hunderte-medikamente-schaedigen-darmbakterien/

Proton pump inhibitors (PPI) therapy and risk of C. diff. infection: Systematic review and meta-analysis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5643276/

FODMAP

Kluyveromyces marxianus-Hefe ermöglicht die Herstellung von FODMAP-armem Vollkornbrot

https://www.ncbi.nlm.nih.gov/pubmed/30166134

Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs

https://www.ncbi.nlm.nih.gov/pubmed/28740352

Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467063/

Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918736/

A diet low in FODMAPs reduces symptoms of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/24076059

Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/21615553

SIBO

A randomized double-blind placebo-controlled trial showing rifaximin to improve constipation by reducing methane production and accelerating colon transit: A pilot study.

https://www.ncbi.nlm.nih.gov/pubmed/30406392

Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.

https://www.ncbi.nlm.nih.gov/pubmed/29508268

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

https://www.ncbi.nlm.nih.gov/pubmed/21208106

Treatment of SIBO

http://www.townsendletter.com/FebMarch2015/sibo0215_2.html

Irritable bowel syndrome and small intestinal bacterial overgrowth: Meaningful association or unnecessary hype

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949258/

How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach

https://www.ncbi.nlm.nih.gov/pubmed/26780631

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/11151884/

Review of rifaximin as treatment for SIBO and IBS

https://www.ncbi.nlm.nih.gov/pubmed/19243285

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504364/

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

https://www.ncbi.nlm.nih.gov/pubmed/20852272

A 14-day elemental diet is highly effective in normalizing the lactulose breath test

https://www.ncbi.nlm.nih.gov/pubmed/14992438

Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome

https://www.ncbi.nlm.nih.gov/pubmed/22523730

Two Independent Networks of Interstitial Cells of Cajal Work Cooperatively with the Enteric Nervous System to Create Colonic Motor Patterns

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3153851/

Update on Irritable Bowel Syndrome Diagnostics and Therapeutics

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969781/

Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth.

https://www.ncbi.nlm.nih.gov/pubmed/20937045

Influence of Saccharomyces boulardii CNCM I-745on the gut-associated immune system (also known as Saccharomyces cerevisiae HANSEN CBS 5926)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027949/

ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth SIBO 2020

ACG_Clinical_Guideline__Small_Intestinal

Adobe Acrobat Dokument 406.0 KB